Our journey to discovering new medicines and vaccines starts by understanding the inner workings of a disease

We follow cutting-edge science to analyze diseases from every angle possible to accelerate the pace of drug discovery – from its underlying genetics, to the structure of individual proteins and the way hundreds of molecules interact with each other. Our scientists are using automation, miniaturization and information technologies as well as new tools – such as our cryo-electron microscope – to help us assess targets at a faster pace and design new medicines. In oncology, we are also evaluating tumor genetics and genomics to identify new targets.

Before breakthroughs, there is science. We ensure only the most promising innovations with the greatest potential advance for future testing

Across the biopharmaceutical industry, it takes many scientists many years to design, make and test thousands of new molecules in order to find the one or two that may be tested in clinical trials. Each discovery is refined, optimized and carefully scrutinized before it can be tested in humans. Our scientists are using preclinical data to conduct translational research to identify biomarkers that can be used in the clinic to provide surrogate measures of efficacy for our investigational candidates.

Our success is due in large part to the challenging scientific questions we set out to answer with our trials and collaborations

Our researchers work internally – as well as with the medical community – to generate evidence to determine whether a medicine has potential to benefit patients. Once our investigational therapies are in clinical trials, our scientists implement machine learning technologies using artificial intelligence to analyze big data from the trials to help us understand the fundamentals of human biology and how that relates to disease modification.

Our Center for Observational and Real-World Evidence (CORE) is dedicated to the science of understanding how our medicines contribute and function in the real world

We believe that real-world evidence, or data acquired in everyday clinical practice, is an important complement to our rigorous clinical trial program. It allows us to take insights from real-world clinical practice back to our research labs to better understand our existing medicines and inform the discovery and development of future therapies.